By Sachin Purwar, Mike Hamlin, & Sophia Tan

The 44th Annual J.P. Morgan Healthcare Conference (JPM 2026) and its sister conference, Biotech Showcase, concluded in San Francisco on January 15, signaling a year defined by disciplined growth, sharpened strategic execution, maturing innovation, and heightened geopolitical complexity. Across pharma, biotech, MedTech, digital health, and healthcare services, leaders expressed measured optimism rooted in strong scientific momentum and improved capital conditions—tempered by policy uncertainty and global competitive shifts.

 

1. Dealmaking Trends: Selective, Strategic, and Value‑Focused

While headline‑grabbing mega‑mergers were limited during JPM week, dealmaking sentiment strengthened meaningfully. Strong Q4 2025 momentum, readily deployable capital, and improving public-market conditions are driving a shift toward high-quality, strategically aligned transactions.

Key Trends:

  • Licensing over mega M&A:
    Large biopharma is prioritizing targeted, high‑impact licensing deals and bolt‑on acquisitions that reinforce pipeline strategy, rather than pursuing transformative mergers.
  • IPO window is reopening:
    Late‑2025 momentum (157% jump in Q4 IPO volume) and early‑2026 offerings (Aktis’ $318m offering in early January immediately followed by Eikon and Veradermics announcing their IPO plans) are signaling renewed investor appetite.
  • Disciplined capital deployment:
    Companies are leaning toward later‑stage, de‑risked assets, differentiated innovation (particularly from China), and programs aligned with upcoming patent cliffs, emphasizing quality over quantity. 

Takeaway:

Capital is available—but discipline governs decisions. Transactions will increasingly favor assets offering clear strategic fit, differentiation, and line‑of‑sight to value.

2026 Outlook:

  • Premiums will concentrate around high‑quality, late‑stage programs.
  • Early‑stage companies must show stronger validation to attract interest.
  • Competition for differentiated assets will intensify as patent cliffs approach.

 

2. China’s Biotech Rise: Reshaping Global Competition

China’s presence at JPM was impossible to ignore. For the first time, discussions positioned China not as a fast follower but as a frontline innovator across modalities, clinical execution, and pipeline diversification. Western companies increasingly rely on Chinese assets to fill pipelines, while China accelerates in complex modalities and clinical execution.

Key Trends:

  • Acceleration in licensing activity:
    Nearly half of U.S./EU in‑licensing deals in 2025 involved Chinese‑developed pipelines, including major deals such as Pfizer – 3SBio, GSK – Hengrui, and Novartis – Argo. The first few weeks of 2026 already produced major deals including Abbvie – RemeGen (up to $5.6b) and AstraZeneca – CSPC (up to $18.5b).
  • Leadership in complex modalities:
    Chinese biotechs are increasingly at the forefront in ADCs, bispecifics, RNAi, cell therapy, and gene therapy—driven by robust scientific talent, aggressive investment, and maturing clinical capabilities.
  • Development & cost efficiencies:
    Faster patient enrollment, lower trial costs, and accelerated data generation are drawing Western companies toward China as both a partner and a competitor.

Takeaway:

China is now a central force in global biopharma—an indispensable innovation hub, a formidable competitor, and a critical strategic variable.

2026 Outlook:

  • Expect expanded East‑West collaborations in high‑value therapeutic areas.
  • Global scouting strategies must treat China as a primary—rather than secondary—source of innovation.
  • Competitive pressure will rise as China continues moving decisively into frontline innovation.

 

3. Policy & Geopolitics: The New Strategic Wild Cards

Policy and geopolitical dynamics shaped a significant share of discussions at JPM 2026. Pricing reforms, IRA implementation, and U.S.–China tensions are now strategic determinants—not background noise.

Key Trends:

  • Pricing reform reshaping valuation:
    Most Favored Nation (MFN) pricing proposals and Inflation Reduction Act (IRA) implementation are influencing launch sequencing, global price corridors, and long‑term asset valuation
  • Geopolitical implications:
    The geopolitical uncertainties and tension are affecting supply chain design, data governance strategies, and cross‑border investment.
  • Policy risk mitigation:
    Companies are building policy risk directly into portfolio and geographic planning to mitigate volatility.

Takeaway:

Policy and geopolitics now sit at the center of strategic planning instead of the periphery.

2026 Outlook:

  • Portfolios must be stress‑tested against varying pricing and reimbursement scenarios.
  • Cross‑border dealmaking will become more cautious and selective, requiring stronger policy fluency.
  • Supply chain resilience and geographic diversification will be imperative.

 

4. AI: Shifting From “Hype Cycle” to “Proof Cycle”

AI has shifted from theoretical promise to measurable enterprise value. Companies showcased real‑world impact across discovery, clinical development, strategic decision making, and operations. At JPM 2026, companies emphasized AI’s ability to accelerate timelines, optimize resources, and de-risk development.

Key Trends:

  • Discovery accelerator:
    AI is compressing discovery timelines and improving target and molecule design, which are especially impactful in complex therapeutic areas.
  • Clinical development efficiency:
    Clinical trials are becoming more efficient through AI‑driven patient recruitment, site selection, adaptive trial design, protocol optimization, and responder identification and stratification.
  • Enterprise strategy optimization:
    Organizations are embedding AI into portfolio prioritization, BD targeting, commercial forecasting, and manufacturing/supply chain optimization. 

Takeaway:

AI is now a core driver of scientific and operational advantage. Execution maturity—not ambition—will differentiate leaders from laggards.

2026 Outlook:

  • AI‑enabled platforms will become standard across R&D and operations.
  • Companies with deeper AI integration will command premium valuations.
  • BD teams will increasingly evaluate AI capabilities as part of partner diligence.

 

5. Emerging Modalities: The Next Wave of Differentiation

JPM 2026 highlighted multiple high‑growth therapeutic and modality areas poised to reshape the industry. These fields combine scientific complexity with strong commercial potential.

Key Trends:

  • ADCs & bispecifics:
    Continue to dominate oncology innovation as strong late‑stage data reinforces their role in next‑generation oncology portfolios
  • Aging, longevity, & brain health:
    Gaining traction as biomarkers mature and aging is reframed as a modifiable biological process.
  • Women’s health:
    Renewed focus on an underfunded, high‑value space—including reproductive health, menopause, and sex‑specific disorders.
  • Radiopharmaceuticals, RNA therapeutics, and gene editing:
    Accelerating through clinical pipelines with strategic partnerships accelerating development and commercialization.

Takeaway:

Emerging modalities represent the next frontier of precision medicine and early movers will gain durable scientific and commercial advantage.

2026 Outlook:

  • Heightened competition for differentiated oncology, neurology, and women’s health platforms.
  • Partnerships will remain essential to access novel modalities and mitigate development risk.
  • Modality selection will become a core strategic lever for long‑term differentiation and investors will reward platforms with validated biology and clear clinical paths.

 

Conclusion:

JPM 2026 delivered a clear message: innovation is booming, but disciplined execution will determine who wins.

Success in 2026 will depend on the ability to:

  • Strengthen pipelines through targeted, data‑driven dealmaking
  • Compete and collaborate effectively in a China‑accelerated global landscape
  • Successfully incorporate and demonstrate ROI in AI and digital transformation
  • Scale precision medicine and next‑generation modalities
  • Navigate policy and pricing headwinds without slowing innovation
  • Build validated business cases for assets that withstand market, regulatory, and investor/partner scrutiny

As the industry enters a year marked by opportunity and complexity, the organizations that thrive will be those that pair strategic clarity with rigorous execution.

The Dedham Group partners with biopharma leaders to develop data-driven insights, anticipate market shifts, optimize commercial strategy, and unlock value across emerging therapeutic and modality landscapes. We welcome the opportunity to discuss how your organization can position itself for success in 2026 and beyond.

 

About the Authors